Aug. 1 Management tracks: R&D chief leaving Adaptimmune; plus Frontier Medicines builds out team and more

Adrian Rawcliffe, the incoming CEO of Adaptimmune Therapeutics plc (NASDAQ:ADAP), said Rafael Amado is leaving the T cell therapy company as president of R&D, effective Aug. 12, to pursue other opportunities. Rawcliffe also announced the promotion of John Lunger to chief patient supply officer, from SVP, manufacturing and supply chain, to build out the company’s manufacturing and supply chain organization.

The company announced in June that CFO Rawcliffe would succeed James Noble as CEO, effective Sept. 1. Noble, who is retiring, will join the board. The company has begun a search for a CMO and CFO...